Showing results (1-10 of 14) with videos related to
Sort By:
Pageof 2
Molecular Medicine Today|August 27, 1999
The oncostatin M signalling pathway: reversing the neoplastic phenotype?S L Grant, C G BegleyClinical and Experimental Pharmacology & Physiology|March 1, 1994
Interaction between epidermal growth factor and arginine vasopressin in renal medullary membranesS L Grant, P A Phillips, C B GowClinical and Experimental Pharmacology & Physiology|October 7, 1997
Effects of indomethacin on epidermal growth factor-induced renal responses in sheepC B Gow, S L Grant, P A PhillipsThe American Journal of Physiology|June 1, 1997
Epidermal growth factor and fluid and electrolyte balance in the ratS L Grant, C B Gow, P A PhillipsGrowth Factors (Chur, Switzerland)|January 29, 2002
Oncostatin M and leukemia inhibitory factor regulate the growth of normal human breast epithelial cellsS L Grant, A M Douglas, G A Goss, et al.Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|August 6, 2013
Scores on the Safe Functional Motion test predict incident vertebral compression fractureN J MacIntyre, C P Recknor, S L Grant, et al.Cancer Chemotherapy and Pharmacology|January 22, 2002
The experimental neuroprotectant leukaemia inhibitory factor (LIF) does not compromise antitumour activity of paclitaxel, cisplatin and carboplatinF M Boyle, C Beatson, R Monk, et al.Growth Factors (Chur, Switzerland)|January 10, 2003
Cytotoxicity of paclitaxel or cisplatin on carcinoma cell lines is not inhibited by leukemia inhibitory factor (LIF)E O'Flaherty, W Cook, J Boyd, et al.Kidney International|April 1, 1994
Epidermal growth factor antagonizes vasopressin in vivo and in vitroP A Phillips, S L Grant, A F Davidson, et al.Molecular Pharmacology|February 29, 2000
Specific regulation of RGS2 messenger RNA by angiotensin II in cultured vascular smooth muscle cellsS L Grant, B Lassègue, K K Griendling, et al.Pageof 2